Skip to contentV
Vistagen Therapeutics, Inc.
V
VTGNVistagen Therapeutics, Inc. Q1 2022 · 10-Q
Revenue$354.10K$354.10K— vs Q1 2021 Net Income-$7.74M-$7.74MN/M vs Q1 2021 EPS Diluted-$0.04-$0.04N/M vs Q1 2021 Operating Income-$7,746,200N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Vistagen Therapeutics, Inc. · CIK 1411685 · Engraved from SEC EDGAR
Free Cash Flowderived-$6,322,800N/M Margins · derivedOperating margin-2187.6%
Net margin-2187.1%
ended Jun 30, 2021 · filed Aug 12, 2021 · 43 d after period end